Nanexa AB (publ) today announces that the annual report for 2023 has been published and is available on the company's website https://nanexa.com/en/financial-reports.

” A year that has brought us closer to commercialization and the expanding type 2 diabetes and obesity market.”

” In 2023, we have delivered in our product projects and in the projects we run together with a number of leading pharmaceutical companies. A year in which we achieved additional results from the use of PharmaShell® that generate interest from the pharmaceutical industry. More clinical data from the completed study in the NEX-20 project and a large amount of data from various preclinical evaluations add important pieces to the puzzle. This includes studying the tissue impact at the injection site, which is very common for injectable depot preparations and especially when administering high doses. We have also met many of the world's leading pharmaceutical companies at conferences that have resulted in great interest in Nanexa and PharmaShell as a drug delivery system. However, no new decisive agreements have been developed during the year. Therefore, we have decided to focus on the activities and projects that we really believe are closest to agreements that can give us both larger revenues in the near future and significant licence revenues going forward”, says David Westberg, CEO of Nanexa.